Interpace Biosciences Reports Q2 2025 Revenue Drop to $9.2 Million, Misses Prior-Year Performance

Interpace Biosciences reported Q2 2025 revenue of $9.2 million, a 23.3% decline YoY, due to the loss of reimbursement for its PancraGEN test. However, the thyroid diagnostics segment achieved record performance, with a 25% increase in revenue to $8.7 million. Gross profit margin fell to 57%, but core thyroid operations excluding PancraGEN showed a 65% margin. The company swung to an operating loss of $0.5 million, impacted by a $1.2 million one-time charge related to the PancraGEN reimbursement loss.

Interpace Biosciences (OTCQX: IDXG) reported mixed financial results for the second quarter of 2025, with net revenue declining by 23.3% year-over-year (YoY) to $9.2 million. Despite the overall revenue decrease, the company's thyroid diagnostics segment achieved record performance, with revenue up 25% YoY to $8.7 million. The company swung to an operating loss of $0.5 million, primarily due to a $1.2 million one-time charge related to the loss of PancraGEN reimbursement. Gross profit margin fell to 57%, but core thyroid operations excluding PancraGEN showed a 65% margin. The company maintains a positive outlook for Q3 2025 and beyond as a thyroid-only diagnostics business.

The company's strong cash collections of $10.8 million and preliminary July 2025 revenue of $3.3 million, marking a 54% increase compared to July 2024, indicate resilience and growth potential. Interpace is transitioning to focus exclusively on thyroid testing following the loss of PancraGEN reimbursement. The company's strategic investments in lab operational efficiency and AI/automation initiatives are expected to drive further growth and profitability.

References:
[1] https://www.stocktitan.net/news/IDXG/interpace-biosciences-announces-second-quarter-2025-financial-and-15jhqtt7ms6n.html
[2] https://www.ainvest.com/news/xplr-2025-q2-earnings-earnings-rise-revenue-decline-2508/